Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether doxycycline (Periostat) at a sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting (CABG) surgery with cardiopulmonary bypass (CPB).

Detailed Description
-----------------
This proposal is for a randomized, placebo-controlled, double-blinded study of the use of doxycycline in patients requiring CABG surgery. Patients will be randomized 1:1 to receive either doxycycline or placebo. This study will be conducted in a blinded manner. The pharmacy will randomize patients and will have the randomization code. The code will only be broken in the case of an emergency and the event will be fully documented. In addition to standard care, patients will receive oral administration of 20 mg of doxycycline or placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3. Myocardial atrial biopsies will be taken at 2 time points during the CABG procedure: during cannulation of the right atrium and 10 minutes after cross-clamp release. Tissue will be analyzed for MMP-2 and -9 activity and TnI and MLC-1 levels. A Swan-Ganz-Catheter will be placed in the pulmonary artery over 24 hours to measure hemodynamics (LVSWI). A coronary sinus catheter will be placed under echocardiographic guidance prior to initiation of CPB (will be removed 20 minutes after cross-clamp release). Patients will have an additional ECG on post-operative days 1 and 3. Additional blood will be drawn to determine doxycycline plasma levels, MMP-2 and -9 activity, total gelatinolytic activity, and levels of troponin I and T products at the following time points: pre-induction, prior to initiation of CPB, 10 and 20 minutes following the release of the aortic cross clamp (arterial and venous) and 3, 6, 24 and 72 hours post aortic cross clamp removal (venous). Each of the above samples will require 6 mL of blood for a study total of 72 mL. At the time of each blood draw we will measure and record the hematocrit value.

Official Title
-----------------
Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting: A Pilot Study

Conditions
-----------------
Coronary Artery Bypass Grafting, Cardiopulmonary Bypass, Reperfusion Injury

Intervention / Treatment
-----------------
* Drug: Periostat
* Drug: Placebo Oral Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent Aged 18 through 80 years, inclusive Scheduled for primary CABG surgery with CPB Exclusion Criteria: Females of childbearing potential Emergency CABG Previous sternotomy Planned simultaneous surgery (i.e. valve repair or carotid endarterectomy) Myocardial infarction within 48 hours Pre-operative atrial fibrillation Pre-operative ventricular pacing or left bundle branch block (LBBB) Known hypersensitivity to tetracycline class antibiotics Renal failure requiring dialysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo oral tablet<br>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it). | Drug: Placebo Oral Tablet<br>* In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.<br>* Other names: Placebo;|
| Experimental: Periostat<br>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it). | Drug: Periostat<br>* In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.<br>* Other names: Doxycycline;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Left Ventricular Stroke Work Index (LVSWI) | Measure of global left ventricular function. The formula used for calculation is: LVSWI= SI x MAP x 0.0144 LVSWI = Left Ventricular Stroke Work Index (g*m/m2) SI = Stroke Index (mL/beat/m2) MAP = Mean Arterial Pressure (mmHg) 0.0144 is a conversion term to equalize units. | Before surgery up to 24h of reperfusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac Matrix Metalloproteinase-9 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion | Biochemical activity of MMP-9 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery. To determine MMP-9 activity, 20 μg of total protein from both myocardial extracts and plasma were analyzed by gelatin zymography. For detailed methodology consult Cheung PY, Sawicki G, Wozniak M, et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101:1833-1839 | Before surgery and 10 minutes reperfusion after surgery | 
| Cardiac Matrix Metalloproteinase-2 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion | Biochemical activity of MMP-2 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery. | Before surgery and 10 minutes reperfusion after surgery | 
| Venous Plasma Cardiac Matrix Metalloproteinase-9 Activity Before and After Reperfusion | Biochemical activity of MMP-9 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery. | Before surgery and up to 72 h reperfusion after surgery | 
| Venous Plasma Cardiac Matrix Metalloproteinase-2 Activity Before and After Reperfusion | Biochemical activity of MMP-2 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery. | Before surgery and up to 72 h reperfusion after surgery | 
| Venous Plasma Concentration of Troponin-I | Measurement of levels of TnI (troponin-I), a marker of cardiac cell damage | Before surgery and 10 minutes reperfusion after surgery | 
| Cleaved TroponinI/GAPDH Ratios in Right Atrial Biopsy | Measurement of the ratios of cleaved TnI (troponin-I) versus GAPDH in biopsies collected from right atria. Measure is the ratio TnI/GAPDH | Before surgery and 10 minutes reperfusion after surgery | 
| Venous Plasma Concentration of C-reactive Protein | Measurement of inflammation marker C-reactive protein in plasma | Before surgery and up to 72 h reperfusion after surgery | 
| Venous Plasma Concentration of IL-6 | Measurement of inflammation marker interleukin-6 in plasma | Before surgery and up to 72 h reperfusion after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Doxycycline, coronary artery bypass grafting